Lipid-Lowering Agents - Greece

Greece

The Lipid-Lowering Agents market in Greece is expected to achieve a revenue of US$25.07m in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of -0.72%, leading to a market volume of US$24.18m by 2029.
Among all countries, United States is anticipated to generate the highest revenue, estimated at US$4,461.00m in 2024.
Greece's lipid-lowering agents market is experiencing a surge in demand due to the high prevalence of cardiovascular diseases in the country.

Key regions: Europe, Brazil, France, Australia, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Greece has been on the rise in recent years.

Customer preferences: The preference for Lipid-Lowering Agents has been driven by the increasing prevalence of cardiovascular diseases in Greece. Patients are increasingly aware of the need to manage their cholesterol levels, and are seeking effective and safe medications to help them do so.

Trends in the market: The market for Lipid-Lowering Agents in Greece is dominated by statins. However, there has been a growing interest in non-statin alternatives, such as PCSK9 inhibitors, which have been shown to be effective in reducing LDL cholesterol levels. The market has also seen the introduction of combination therapies, which offer the convenience of taking multiple medications in a single pill.

Local special circumstances: Greece has a high prevalence of cardiovascular diseases, which is driving the demand for Lipid-Lowering Agents. The country also has a high proportion of elderly population, who are more likely to suffer from cardiovascular diseases. The Greek healthcare system has been under pressure in recent years due to the economic crisis, which has led to a reduction in healthcare spending. This has resulted in a shift towards more cost-effective treatments, such as generic statins.

Underlying macroeconomic factors: The Greek economy has been recovering in recent years, which has led to an increase in healthcare spending. The government has also introduced reforms to the healthcare system, which aim to increase efficiency and reduce costs. However, the healthcare system in Greece still faces challenges, such as limited resources and an aging population. The Lipid-Lowering Agents market is expected to continue growing in the coming years, driven by the increasing prevalence of cardiovascular diseases and the availability of new treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.